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Individuals with diabetes suffering from coronavirus dis-
ease 2019 (COVID-19) exhibit increased morbidity and
mortality compared with individuals without diabetes. In
this Perspective, we critically evaluate and argue that
this is due to a dysregulated renin-angiotensin system
(RAS). Previously, we have shown that loss of
angiotensin-I converting enzyme 2 (ACE2) promotes the
ACE/angiotensin-II (Ang-II)/angiotensin type 1 receptor
(AT1R) axis, a deleterious arm of RAS, unleashing its
detrimental effects in diabetes. As suggested by the re-
cent reports regarding the pathogenesis of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), upon
entry into the host, this virus binds to the extracellular
domain of ACE2 in nasal, lung, and gut epithelial cells
through its spike glycoprotein subunit S1.We put forth the
hypothesis that during this process, reduced ACE2 could
result in clinical deterioration in COVID-19 patients with
diabetes via aggravating Ang-II–dependent pathways and
partly driving not only lung but also bone marrow and
gastrointestinal pathology. In addition to systemic RAS,
the pathophysiological response of the local RAS within
the intestinal epithelium involves mechanisms distinct
from that of RAS in the lung; however, both lung and
gut are impacted by diabetes-induced bone marrow dys-
function. Careful targeting of the systemic and tissue RAS
may optimize clinical outcomes in subjects with diabetes
infected with SARS-CoV-2.
This Perspective focuses on providing an overview of
recent studies describing the impact of the coronavirus
disease 2019 (COVID-19) pandemic on individuals with
diabetes and several possible mechanisms for why indi-
viduals with diabetes represent a particularly at-risk pop-
ulation. In December 2019, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) was identified as
the pathogen responsible for the outbreak that began in
Wuhan, China, and rapidly spread throughout China,
Europe, and the U.S. Currently, the SARS-CoV-2 virus has
infected more than 12 million individuals worldwide, with
more than 555,000 COVID-19 cases resulting in death,
and the number of individuals becoming infected is in-
creasing. Thus far, SARS-CoV-2 mechanisms of infectivity
remain incompletely understood. Some insight, however,
has been provided by the previous pandemic of SARS-CoV
in 2002, but the brutality of COVID-19 has raised many
unanswered questions and the pace of science needs to
increase. Here, we put forth the argument that a dysregu-
lated renin-angiotensin system (RAS), typically seen in
individuals with diabetes, increases the risk of a poor
clinical outcome following COVID-19 infection.
Clinical Burden of COVID-19 in Patients With Diabetes
Conditions associated with increased morbidity and mor-
tality in individuals infected with SARS-CoV-2 are the
presence of diabetes, hypertension, cardiovascular disease,
and severe obesity (BMI $40 kg/m2) (1–3). Considering
the high prevalence of hypertension, cardiovascular dis-
ease, and obesity in individuals with diabetes, it is difficult
to know how diabetes alone directly contributes to the
increased risk of adverse outcomes following SARS-CoV-2
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infection. Studies indicate that 12–16% of individuals with
severe infections have diabetes (1,2). However, a recent
meta-analysis of six clinical studies involving 1,687
COVID-19 patients provided evidence that individuals
with diabetes exhibited a similar prevalence of being
infected with SARS-CoV-2 as the overall population,
but presence of diabetes was a critical comorbidity that
increased the risk of a poor outcome (4). Certain racial
groups such as African Americans and Native Americans
are highly prone to developing diabetes and experience
disparities in health care making them particularly vul-
nerable to COVID-19 (5). However, to date there is a pau-
city of data regarding comorbidities, COVID-19 outcomes,
and mechanisms that modulate viral pathogenesis. In this
Perspective, we bring attention to specific factors that may
complicate COVID-19 in individuals with diabetes includ-
ing 1) the presence of bone marrow changes (myeloidosis)
that predispose those with diabetes to an excessive proin-
flammatory response (cytokine storm) and contribute to
insulin resistance and reduced vascular repair, and wors-
ening function of the heart, kidney, and systemic vascu-
lature as a whole; 2) increased circulating furin levels that
could cleave the spike protein and increase infectivity of
SARS-CoV-2; 3) dysregulated autophagy that may promote
replication and/or reduce viral clearance; and 4) gut dys-
biosis that leads to widespread systemic inflammation,
increased gut glucose and sodium absorption, and reduced
tryptophan and other key amino acid absorption needed
for incretin secretion and glucose homeostasis. Central to
each of these dysfunctions is the dysregulated RAS, in
particular, the global loss of ACE2, which we propose is
a unifying mechanism that could lead to the increased risk
of morbidity and mortality in individuals with diabetes
presenting with COVID-19.
Biochemistry and Physiology of RAS
The RAS is a key hormonal circuit tasked in regulating
extracellular fluid volume and blood pressure in mammals.
If blood pressure falls, the juxtaglomerular cells in the
kidneys produce and secrete renin, which cleaves serum
angiotensinogen to produce angiotensin I (Ang-I). Then,
angiotensin-I converting enzyme (ACE) further converts
Ang-I into angiotensin II (Ang-II) in the lungs by removing
the C-terminal dipeptide from Ang-I (Fig. 1). Ang-II in turn
activates the G-protein–coupled angiotensin type 1 recep-
tor (AT1R) on adrenal zona glomerulosa cells to produce
aldosterone, which causes sodium retention, an increase in
blood volume, and blood pressure stabilization. Besides its
beneficial function in regulating extracellular fluid volume,
a dysregulated RAS, as seen in diabetes, could lead to an
increase in serum levels of Ang-II that could cause a pleth-
ora of potentially harmful effects including vasoconstric-
tion, inflammation, and increased oxidative stress. ACE2
converts Ang-II into Ang-1-7, and Ang-1-7 acts through
the Mas receptor (MasR) to oppose the effects of Ang-II.
This ability of ACE2 to convert the serum vasopressor
Ang-II into the vasodilating Ang-1-7 identifies it as
a “negative” regulator of RAS. Notably, COVID-19 patients
exhibit increased serum levels of Ang-II (6), which would
support less cleavage by ACE2 and thus potentially less
ACE2 activity. In addition to systemic RAS, “local” RAS
exists within each tissue including a lung RAS, intestinal
RAS, and bone marrow RAS. Interestingly, the RAS system
in the intestinal mucosa significantly contributes to the
regulation of glucose, salt, and water uptake. Emerging
COVID-19 gastrointestinal disturbances implicate a central
role of intestinal pathophysiology in exacerbation of hy-
perglycemia and blood pressure in individuals with di-
abetes infected with SARS-CoV-2.
ACE2 PROTEIN: FUNCTION, INTERACTION
BETWEEN ACE2 AND ADAM17, AND ACE2 AS THE
RECEPTOR FOR SARS-COV AND SARS-COV-2
ACE2 was discovered in 2000 (7), just 2–3 years before
the first wave of SARS-CoV coronavirus pandemic, when
ACE2 was identified as the major SARS-CoV “receptor” on
host cells. ACE2 functions as a metallocarboxypeptidase,
a plasma membrane–bound proteolytic enzyme (Fig. 2A)
that removes a single carboxy-terminal amino acid from
specific bioactive oligopeptides, such as Ang-I and Ang-II to
form Ang-1-9 and Ang-1-7, respectively (Fig. 1). Unlike
ACE, which is a peptidyl dipeptidase removing two car-
boxy-terminal amino acids from Ang-I and Ang-1-9, ACE2
is not inhibited by typical ACE inhibitors, such as captopril.
The ectodomain of ACE2 can be shed into the systemic
circulation as a soluble protein, preserving the catalytic
activity of ACE2 (soluble ACE2) and its ability to generate
in the circulation the vasoprotective peptide, Ang-1-7.
Shedding of the ACE2 ectodomain occurs after proteolytic
cleavage by plasma membrane–anchored endopeptidases,
enzymes capable of breaking nonterminal peptide bonds,
such as a disintegrin and metallopeptidase domain 17 pro-
tein (ADAM17) (8) or the type II transmembrane serine
proteases (TMPRSS2) (9).
Human ACE2 (hACE2) is predominantly expressed in
the nasal epithelium, airways, lungs, heart, adipose tissue,
kidneys, small intestine, and colon (7,10–12). The high
density of hACE2 is found in human nasal epithelium
goblet cells, human ciliated cells of the airways, the type
2 alveolar (AT-2) epithelial cells, and bronchial transient
secretory cells (10,11). High hACE2 expression in the nasal
epithelium is consistent with clinical observations that
symptomatic individuals with COVID-19 present with
a higher viral load in the nasal cavity compared with
the throat (10) and that some COVID-19 patients com-
plain of inability to smell (13). The hACE2-expressing nasal
epithelium may provide an “intermediate site” for viral
replication before its invasion of the lungs to cause symp-
tomatic COVID-19 and may serve as a sanctuary niche for
SARS-CoV-2 survival without spreading to the lungs in
human subjects, thus perhaps permitting asymptomatic
human-to-human transmission. Notably, the SARS-CoV-2
positive individuals may shed the virus for up to 37 days
(3).
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The ACE2 protein contains two cofactors: Zn21 and Cl2
ions (Fig. 2A). The zinc binding site, coordinating Zn21, is
critical for the catalytic activity of ACE2 and consists of
H374-E375-X-X-H378 in hACE2. The Cl2 binding site
regulates the efficacy of ACE2 to cleave its substrates
(Ang-I and Ang-II) in an extracellular Cl2-dependent man-
ner (7).
The spike proteins of SARS-CoV and SARS-CoV-2 bind
themembrane-bound ACE2 to enter the host cells (14–16).
The interface of the SARS-CoV-2 receptor binding domain
located on the S1 subunit of the spike protein and the
N-terminal segments of hACE2 was mapped using cryo-
EM and X-ray crystallography (Fig. 2B) (17–19), and the
structure data shed light on the underlying mechanisms.
There are several virus binding hotspots on the surface of
hACE2 that are critical for virus infectivity; these include
hotspot 31 (lysine 31), hotspot 353 (lysine 353), and the
hydrophobic interaction site (tyrosine Y83) (17). Com-
pared with SARS-CoV, SARS-CoV-2 forms additional hy-
drogen bonds, dipole-dipole interactions, and salt bridges
(19), suggesting stronger interaction. The affinity binding
data indicate that the receptor binding domain of SARS-
CoV-2 has a greater affinity to hACE2 compared with that
of the SARS-CoV virus (17), potentially explaining the
enhanced ability of SARS-CoV-2 to quickly spread and
infect a great number of hosts. While membrane-bound
hACE2 is the major cellular receptor for SARS-CoV-2
binding and internalization, the soluble form of hACE2
is efficient at preventing the coronaviruses attachment to
the membrane-bound hACE2 (20).
Proteolytic cleavage of the homotrimeric spike protein
ectodomains at the S1/S2 subunit junction is critical for
entry of coronaviruses into host cells. The ectopeptidase
TMPRSS2 and endosomal peptidases cathepsin B/L are the
major cellular enzymes that mediate coronavirus “priming”
in SARS-CoV-2 (14) by cleaving the spike protein at the S1/
S2 cleavage site (IAY↓TMS) (Fig. 3). The SARS-CoV-2 spike
protein has an additional canonical furin cleavage site
(PRRAR↓SV) located upstream of the conserved IAY↓TMS
cleavage site (15,21). This is a unique property of SARS-
CoV-2 because the furin site is not present in SARS-CoV
(15,21). The presence of a furin-like cleavage site in viral
spike-shaped hemagglutinin proteins has been associated
with an increased virulence and pathogenicity in avian and
human influenza viruses. Consistently, the current pan-
demic epidemiological data confirm the increased trans-
missibility and pathogenicity of SARS-CoV-2 as compared
with SARS-CoV (22).
Figure 1—The biochemical pathways of the RAS and the beneficial ACE2/Ang-1-7 arm of RAS. The amino acid sequences of hormones are
colored in blue and enclosed in parentheses. Renin is produced and secreted in the juxtaglomerular cells of the kidney when plasma NaCl
decreases or blood pressure falls. Renin cleaves angiotensinogen to produce Ang-I, which is further converted into Ang-II by ACE in the
lungs. Ang-II induces aldosterone secretion from adrenal zona glomerulosa cells, which in turn promotes sodium and water retention in the
kidneys, increasing blood pressure. Thus, initial serum Ang-II levels are set by renin. However, the steady-state serum Ang-II level is also
markedly affected by the rate of its conversion to Ang-1-7 by ACE2. Therefore, ACE2 activity contributes to regulating the steady-state levels
of Ang-II. If we consider an example of a rainwater barrel and assume that renin is the actual rainfall amount, Ang-II is the rainwater, and ACE2
activity is the barrel’s outlet spigot, then the rainfall amount (renin) would always determine the rainwater (Ang-II) inflow rate and level into the
barrel. But if we would keep the barrel outlet spigot always open (ACE2 is active) during and after rainstorms, the final level of rainwater would
not be as high as in the case if the barrel’s outlet spigot were closed (ACE2 is inactive). Aldo, aldosterone; ZG, zona glomerulosa.
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The structure of the SARS-CoV-2 spike protein provides
insight on why the addition of the furin cleavage site may
increase transmissibility of the virus. According to the
structure, the TMPRSS2 cleavage site (IAY↓TMS) is located
in a shallow pocket on the lateral surface of the SARS-CoV-
2 spike protein (Fig. 3), whereas the short solvent-exposed
protein loop harboring the furin-cleavage site (not solved
in the structure and shown as the dotted lines in Fig. 3)
appears to hang over the TMPRSS2 cleavage site, obstruct-
ing access. The newly biosynthesized SARS-CoV-2 viral
particles are likely released by budding in a Golgi com-
partment–dependent manner. Since furin is a Ca21-de-
pendent endopeptidase, which is present and active only in
the Golgi compartment (Fig. 4), the complete cleavage of
the furin site is expected in Golgi compartment–processed
SARS-CoV-2 spike proteins and is experimentally con-
firmed (15). Furin-cleaved S1/S2 subunits remain non-
covalently bound in the homotrimeric spike protein
assembly. It is possible that in the furin precleaved
SARS-CoV-2 spike protein, the TMPRSS2 cleavage site is
no longer obstructed and is more accessible for TMPRSS2
and/or cathepsins. However, experimental confirmation
will be needed for this hypothesis. The SARS-CoV-2 spike
protein can be in the closed (folded) or open conformation
when the viral receptor binding domain unfolds and
extends above the trimeric spike protein structure (Fig.
3). Whether furin cleavage affects the equilibrium between
the two spike protein conformations also remains unclear
and awaits experimental evidence.
As COVID-19 progresses, SARS-CoV-2 may also involve
the lytic release pathway for newly produced viral particles,
bypassing the budding process utilizing the furin-contain-
ing Golgi compartments (Fig. 4). In such cases, the spike
protein of SARS-CoV-2 may remain at least partially
uncleaved by intracellular furin. At this stage of COVID-
19, extracellular furin may be utilized to complete the
cleavage of spike protein’s furin cleavage sites, facilitating
the virus spread in the infected host. Notably, circulating
levels of furin are elevated in patients with diabetes (23),
and patients with diabetes infected with SARS-CoV-2
present with increased mortality (4) and delayed recovery
from SARS-CoV-2 infection. Also, individuals with high
plasma furin concentration typically have a pronounced
dysmetabolic phenotype and elevated risk of diabetes.
RAS Modulates Autophagy
There is increasing evidence that dysregulated autophagy
contributes to the pathogenesis of diabetes and its com-
plications. Autophagy is primarily recognized for its es-
sential role in cellular housekeeping and homeostasis
through the sequestration and transfer of intracellular
components to lysosomes for degradation. However, the
Figure 2—A: Block diagram of the hACE2 protein segments and the structure of its soluble domain, which is shed from the full-length hACE2
after cleavagewith endopeptidases, such as ADAM17, is shown. The cyan segment depicts the location of the endopeptidase cleavage sites.
The amino acids at the borders of the segments are shown in black. The structure depicts the locations of zinc (catalytic) and chloride
(regulatory) binding sites. The Cl2 binding site, coordinating a single Cl2 anion, regulates the efficacy of ACE2 to cleave its substrates (Ang-I
and Ang-II). Specifically, ACE2-mediated removal of the terminal leucine from Ang-I is potentiated, whereas the cleavage of the terminal
phenylalanine from Ang-II is inhibited in the presence of extracellular chloride anions. The structure of the hACE2 was replotted from pdb ID:
1R42 (50). CD, cytosolic domain; TMD, transmembrane protein.B: The interface of the SARS-CoV-2 virus (brown) and the N-terminal domain
of hACE2 (green). The open red circles show the interaction hotspots similar to those identified for the SARS-CoV virus. The catalytic site of
hACE2 is visible in the left upper corner. The structure of the hACE2 bound to SARS-CoV-2 receptor binding domain (RBD)was replotted from
pdb ID: 6M0J (19).
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endocytic pathway and autophagy are key processes af-
fecting virus infection and replication, including the coro-
navirus family (24). Viral RNA replication in coronavirus-
infected cells occurs in double membrane vesicles that
resemble autophagosomes (Fig. 4). Additionally, nonstruc-
tural protein 6 (nsp6) of SARS-CoV-2 can generate auto-
phagosomes, and an associated mutation in nsp6 is
identified in COVID-19 patients (4,24). Interestingly, in-
hibition of the canonical autophagy pathway, using in vitro
approaches, does not appear to have an effect on SARS-
CoV replication, suggesting a noncanonical process. How-
ever, a key autophagy protein, LC3, colocalizes with viral
replication-transcription complexes, and an S-phase ki-
nase-associated protein 2 (SKP2) reduces autophagy pro-
tein Beclin1 levels in coronavirus infections (24,25). In
both cases, fusion between autophagosomes and lyso-
somes is blocked, leading to an accumulation of autopha-
gosomes favoring replication of the virus. Inhibiting SKP2
or enhancing autophagy flux has been shown to reduce the
replication of coronaviruses (24,25). RAS can be an im-
portant regulator of autophagy. Ang-II activation of an-
giotensin type 2 receptor (AT2R) attenuates autophagy,
whereas Ang-II activation of AT1R induces autophagy
through AMPK/mTOR signaling. Ang-1-7 induces autophagy
via the cofilin receptor (26). Activation of intestinal RAS
promotes Paneth cell autophagy leading to bowel in-
flammation and arrested release of antimicrobial factors
including defensin 5, which inhibits SARS-CoV-2 infection
by cloaking ACE2 (27). Given the strong association be-
tween the RAS and autophagy, both may serve as ther-
apeutic targets to ablate SARS-CoV-2 infection and
replication, and this may further explain the possible
beneficial effects of ACE inhibitors/ATR blockers in the
treatment of COVID-19, discussed further below.
A Dysregulated RAS May Increase Adverse Outcomes
in Individuals Infected With SARS-CoV-2
Several mechanisms may contribute to increased severity
of COVID-19 progression in subjects with diabetes. Indi-
viduals with diabetes are more vulnerable to most infec-
tions and may exhibit decreased viral clearance due to
reduced neutrophil chemotaxis, phagocytosis, and intra-
cellular killing of microbes. Under noninfectious condi-
tions, chronic diabetes in both human and rodent models
was associated with myeloidosis (7), with monocytes
expressing higher levels of proinflammatory cytokines
that may, in patients with acute respiratory distress syn-
drome (ARDS), contribute to cytokine storm.
Once bound to ACE2, SARS-CoV was shown to down-
regulate cellular expression of ACE2, and the unopposed
action of Ang-II was deemed responsible for worsening
lung injury (28). Whether this is the case with SARS-CoV-2
is not known. Ang-II receptor blockers, ACE inhibitors,
thiazolidinediones, incretin GLP-1 agonists, and statins
Figure 3—Block diagram of the homotrimeric SARS-CoV-2 spike protein assembly. “RBD” stands for receptor binding domain, “FP” stands
for fusion peptide, and the IPF block depicts the location of internal fusion peptide. S1 and S2 are two segments of SARS-CoV-2 ectodomain
that can be cleavedwith the indicated endopeptidases. The cryo-EM structure (15) of the spike protein is shown in the center of the figure. The
proteolytic sites are shown in green. In the structure, the residues preceding and following the furin cleavage site are colored in brown. The
inset shows a magnifying view of the TMPRSS2/cathepsin cleavage site. The structure of the homotrimeric SARS-CoV-2 spike protein
complex was replotted from pdb ID: 6VYB (15). Each spike protein in the homotrimer is color coded for better identification.
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Figure 4—Diagram of the SARS-CoV-2 virus life cycle. SARS-CoV-2 is a member of theCoronaviridae subfamily and belongs to the genus of
b-coronaviruses. This is a positive-sense single-stranded RNA virus. SARS-CoV-2 viral RNA serves to code the viral genome and as mRNA
for direct protein translation by the host cell ribosomes. Indeed, viral RNA contains a poly-A tail at the 39 end and a typical mRNA cap structure
at the 59 end. SARS-CoV-2 viral RNA is nonsegmented. Viral RNAgenome translation startswith the production of two replicase polyproteins,
pp1a and pp1ab, which consist of 11 or 16 covalently linked nonstructural proteins (nsp), respectively. These two large polyproteins are
subject to proteolytic cleavage by proteases resulting in the formation of individual nsp1–nsp16. Viral nsp3 functions as a papain-like
protease and is important for cleaving the interdomain junctions between nsp1 and nsp4, whereas nsp5 is a chymotrypsin-like protease,
which is also named “main protease” because it is responsible for cleaving interdomain junctions between nsp4 and nsp16. Nsp6 can induce
small-diameter autophagosome formation in infected cells. Nsp12 (RdRp) is an RNA-dependent RNA polymerase, which is critical for a large-
scale replication of viral RNA. Nsp12 requires several cofactors, such as nsp7 and nsp8. The RNA helicase nsp13 (Hel) is important for
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are typical medications for diabetes that are known to
increase ACE2 expression. Lack of evidence regarding the
risk or benefit of ACE inhibitors and angiotensin receptor
blockers (ARBs) has resulted in the American College of
Cardiology, American Heart Association, American Society
of Hypertension, and European Heart Association recom-
mendations that patients should continue treatment with
their usual antihypertensive therapy (29). However, we
would propose that drug-induced increases in ACE2 ex-
pression would potentially be beneficial in subjects with
diabetes by increasing Ang-1-7 and shifting the RAS axis
away from the profibrotic, proinflammatory arm of RAS.
Thus, in subjects with diabetes, infection with SARS-CoV-2
would potentially result in additional loss of ACE2 expres-
sion in blood vessels and could exacerbate the already
compromised vasculature (29).
Implications of COVID-19 Infection on Bone Marrow
Dysfunction and Increasing Severity of Diabetic
Vascular Complications
The existence of specific RAS systems in organs including
the bone marrow has been well established. Local RAS is
active in primitive embryonic hematopoiesis (30) and
continues to regulate each stage of physiological and
pathological blood cell production in the adult via auto-
crine, paracrine, and intracrine pathways. Local RAS pep-
tides directly regulate myelopoiesis, erythropoiesis,
thrombopoiesis, and the development of other cellular
lineages (31).
The bone marrow plays a critical role in the pathogen-
esis of diabetic complications. Individuals with diabetes
with vascular complications typically have reduced num-
bers and migratory function of bone marrow–derived
vascular reparative cells, called circulating angiogenic cells
(CACs or CD341 cells). Ang-1-7 improved migration, re-
stored bioavailable nitric oxide, and reduced reactive ox-
ygen species in diabetic CACs. Ang-1-7 gene modification
of CACs restored the cells in vivo vasoreparative function
(32). A unique set of individuals with diabetes that
remained free of microvascular complications, despite.40
years of poor glycemic control, had higher mRNA levels for
ACE2 and MasR in their CACs compared with age-, sex-,
and glycemia-matched individuals with diabetes with
microvascular complications (32). In Akita mice, global
loss of ACE2 (ACE22/y–Akita mice) was associated with
a reduction of hematopoietic stem/progenitor cells (HS/
PC), a shift of hematopoiesis toward myelopoiesis in bone
marrow, and an impairment of HS/PC migration and
proliferation. Migratory and proliferative dysfunction of
these cells was corrected by exposure to Ang-1-7 (33).
These data support that activation of the protective RAS is
beneficial for the dysfunctional diabetic bone marrow.
Diabetes-associated bone marrow dysfunction and loss
of vascular reparative cells, such as CACs, may contribute
to vascular dysfunction in COVID-19 patients that can be
manifested as cardiac disease including arrhythmias, viral
myocarditis, heart failure, and cardiac arrest (34–36). The
impact of global loss of ACE2 in cardiac dysfunction is
supported by preclinical studies showing that hearts from
Akita mice exhibit marked systolic dysfunction and that
ACE22/y-Akita mice show impaired flow-mediated dilation
of the femoral artery in response to ischemia/reperfusion
injury, indicative of endothelial dysfunction. In contrast,
gain-of-function studies using ACE2 overexpression, via
adenoviral gene delivery, in type 1 diabetic rats decreased
collagen accumulation and improved left ventricular
remodeling and function (7).
The impact of dysregulated RAS is seen in obesity and
type 2 diabetes models. Heart failure with preserved
ejection fraction (HFpEF) is a proinflammatory state
closely linked to obesity-related cardiovascular dysfunc-
tion. Loss of ACE2 increases epicardial adipose tissue
macrophage polarization to proinflammatory M1-like phe-
notype and worsens HFpEF in response to diet-induced
obesity. Ang-1-7 has potent anti-inflammatory effects in
adipose tissue of obese type 2 diabetic mice and protects
against diabetic cardiomyopathy and nephropathy. Impor-
tantly, Ang-1-7 decreased macrophage M1 polarization
and preserved cardiac function in diet-induced obese
ACE2 knockout mice (7).
In COVID-19 patients, the prevalence of kidney dis-
ease on admission and the development of acute kidney
injury during hospitalization is high and associated with
in-hospital mortality (37). Patients with diabetes with
nephropathy have reduced ACE2. Global loss of ACE2
replication. Nsp14 is a viral N7-methyltransferase ensuring the fidelity of replication. The viral RNA also encodes four structural proteins: the
spike protein (S), envelop protein (E), membrane protein (M), and nucleocapsid protein (N). In SARS-CoV-2 virions, viral RNA is envelopedwith
a membrane that is stabilized by the imbedded structural proteins, including S, E, M, and N proteins. The S or spike protein is a homotrimer
that gives the viral particles a characteristic appearance of spiky corona. The S protein is critical for the viral entry into the host cells. The S1
subunit of the SARS-CoV-2 spike protein utilizes the hACE2 protein as its cellular receptor. The TMPRSS2 protein is the key endopeptidase
that is important for priming the spike protein of SARS-CoV-2, allowing viral entry into host cells. Cathepsin B/L is an endosomal protease that
can substitute TMPRSS2 activity during spike protein priming before viral RNA gains access into the cellular cytosolic compartments. SARS-
CoV-2 replication takes place in double membrane vesicles (DMV) that are associated with the specific areas of the rough endoplasmic
reticulum or other intracellular membranes, including autophagosomal membranes. The M, E, and N structural proteins together with the S
protein are important for formation and stabilization of the SARS-CoV-2 viral particles. Viral structural protein modification takes place in the
Golgi compartment before viral particles are ready for budding. Furin is a Ca21-dependent endopeptidase enriched in the Golgi compart-
ments that precleaves the spike protein at a specific cleavage site in the Golgi compartments, with S1 and S2 subunits remaining
noncovalently bound in budding virions. ADAM17 proteolytic activity generates soluble hACE2.
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exacerbates diabetic kidney injury while potentiating Ang-
II–mediated cardiorenal fibrosis and oxidative stress in the
heart and kidney (7). In Akita mice, recombinant hACE2
(rhACE2) treatment for 4 weeks resulted in decreased
glomerular mesangial matrix expansion, which was asso-
ciated with increased Ang-1-7 levels and lowered Ang-II
levels, along with reduced NADPH oxidase activity. The
loss of ACE2 via ADAM17 proteolytic cleavage, which is
strongly activated in COVID-19 patients, will likely pro-
mote further injury to the cardiovascular system and
kidneys in patients with diabetes (7,38). Importantly,
ACE2 overexpression increases the antihypertensive com-
ponents of the RAS and pretreatment with rhACE2 pre-
vents Ang-II–induced hypertension in preclinical experimental
models. However, these results have yet to be validated in
human hypertension.
While the lung is not considered a target tissue for
diabetic complications, COVID-19 patients with diabetes
experience worse pulmonary disease than those without
diabetes. ACE2 knockout mice exhibit ARDS pathology.
ARDS triggers multiple pulmonary diseases and is ob-
served in COVID-19 patients. Importantly, ACE deficiency
or treatment with AT1R blockers of ACE22/y mice rescue
them from ARDS (38). Taken together, these studies
support that in individuals with diabetes with vascular
complications, the loss of the protective RAS would serve
to intensify SARS-CoV-2–induced pathology.
SARS-CoV-2 Hijacks Gastrointestinal ACE2, Local
RAS, and Transporters
The recent demonstration of SARS-CoV-2 actively infect-
ing human enterocytes and the mounting gastrointestinal
symptomology implicate gastrointestinal tract pathophys-
iology in COVID-19 infection (12,39). The digestive system
possesses the body’s site of greatest relative expression of
ACE2, which in the gut exists as a tetramer with B0AT1
(Fig. 5). While B0AT1 is not expressed in lung pneumo-
cytes, ACE2:B0AT1 complex in the gut acts as a central
player in local gut RAS and regulates uptake of glucose,
sodium, water, and amino acids (40–42). However, ACE2:
B0AT1 complex internalization by SARS-CoV-2 (Fig. 6)
destabilizes the gastrointestinal tract’s role in diabetes
and blood pressure regulation (Fig. 7).
B0AT1 (SLC6A19) is the intestine’s primary epithelial
apical membrane transporter serving Na1-coupled uptake
of neutral amino acids, such as tryptophan. B0AT1 was
originally discovered and its functionally characterized by
Stevens et al. (43), and the transporter was initially named
NBB, B, B0, or B(0) in the literature but was subsequently
called B0AT1. ACE2 chaperones the trafficking of B0AT1 to
form the stabilized dimer of ACE2:B0AT1 (18) in the apical
membrane (Fig. 5). Importantly, B0AT1 substrates, notably
tryptophan and glutamine, signal downregulation of lym-
phoid proinflammatory cytokines, promote tight junction
formation, activate the release of antimicrobial peptides,
and modulate mucosal cell autophagy as defense mecha-
nisms. In the models shown in Figs. 6 and 7, binding of
SARS-CoV-2 S1 to ACE2 (18) (Fig. 6) results in down-
regulating both intestinal ACE2 and B0AT1, with conse-
quences of disrupting sodium and glucose transport,
promoting leaky gut syndrome, elevating plasma bacterial
lipopolysaccharide, and enhancing inflammation (Figs. 5
and 7).
Intestine, lumen-facing ACE, and ACE2 participate in
the food digestion process, but are also intertwined in
cross talk with gut microbiome metametabolomics of bio-
active peptides. Such peptides include a balance of agonists
and antagonists of enterocyte apical membrane MasR and
AT1R, which are physiologically tasked with regulating
uptake of dietary Na1 via NHE3 and glucose absorption
via SGLT1 and GLUT2 (Fig. 6).
SARS-CoV-2 Modulation of Insulin and Glucose
Intestinal ACE2:B0AT1 dimer of heterodimers promotes
enterocyte Na1-coupled uptake of phenylalanine, glutamine,
tryptophan and its microbiome-generated metabolites,
and other neutral amino acid agonists of nutrient-sensing
receptors. These stimulate release of GLP-1 and GIP into
the blood from gut mucosal enteroendocrine L cells (Fig. 6)
(44). These incretins circulate to activate pancreatic
b-cells, suppress a-cells, and afford brain satiety. SARS-
CoV-2 infection of gut mucosa results in endocytosis of
apical ACE2, thereby downregulating its activity (45),
resulting in gut luminal accumulation of AT1R agonist
peptides and disrupting all functions of B0AT1.
Gut–Bone Marrow Connection in Individuals With
Diabetes Infected With COVID-19
The dysregulated RAS in the bone marrow with its accom-
panying myeloidosis promotes chronic inflammation that
can contribute to both lung and gut pathology (Fig. 7). An
extensive literature supports the concept of communica-
tion between the gut and bonemarrow. The gut microbiota
is a critical extrinsic regulator of hematopoiesis (46), as
very low concentrations of microbial antigens set the size
of the bone marrow myeloid cell pool, and the size of this
pool correlates strongly with the complexity of the in-
testinal microbiota. In turn, bone marrow cells migrate to
the gut and impact gut function via changes in blood flow,
gut immunity, and epithelial and endothelial tight junction
integrity. Recruitment of bone marrow–derived immune
cell to the gut is necessary for host defense and contributes
to inflammation resolution and tissue healing. Loss of
ACE2 in diabetes results in phylogenetic differences in
the gut bacterial community composition with increases in
bacteria that have been associated with peptidoglycan
generation, which promotes systemic inflammation (47).
Overactivation of bone marrow–derived immune cells in-
cluding proinflammatory monocytes results in secretion of
a large number of harmful cytokines into the circulation
that promotes insulin resistance. In the patient with di-
abetes infected with COVID-19, developing pneumonia
can be devastating, as preexisting systemic inflammation
can rapidly lead to multiple organ failure. Inflammatory
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cytokine storm is a notable cause of death in critically ill
COVID-19 patients and may be driven as much by gut-
induced inflammation as lung injury. Thus, imbalance in
the bone marrow RAS system (Fig. 7) may represent
a central mechanism to not only initiate but also propagate
lung and gut injury.
Possible Therapeutics That Modulate RAS
From the perspective of gut enterocyte local RAS, orally
delivered ACE inhibitors upregulate expression of both
intestinal ACE2 and B0AT1 with their attending nutrient-
signaled release of GLP-1, GIP, and mucosal antimicrobial
peptides (40) (Fig. 6). In a preclinical colitis model, the ARB
irbesartan restored intestinal B0AT1 and ACE2 expression
and tryptophan homeostasis with concurrent reduction of
intestinal inflammasome activity through an mTOR S6
kinase pathway (48). Irbesartan further shifted the gut
microbiota composition toward favorable taxa and away
from stress-related dysbiosis (48). Activation of enterocyte
AT1R signaled apoptosis with reduced mucosal villus
height, while losartan-mediated blockage of gut AT1R
resulted in increased mucosal cell proliferation and re-
duced apoptosis.
Increasing gut ACE2 by engineering probiotic species
such as Lactobacillus paracasei (LP) to express this
recombinant protein was a strategy used to prevent mi-
crovascular complications in diabetic mice. LP expressing
the secretable ACE2 fused with the nontoxic subunit B of
cholera toxin (which acts as a carrier to facilitate trans-
mucosal transport), showed increased ACE2 activities in
serum and tissues, and reduced diabetic complications
(49). These results provide proof of concept for feasibility
of using engineered probiotic species as a live vector for
delivery of decoy hACE2 for possible treatment of enteric
COVID-19 infection.
rhACE2 given as intravenous medication may be ex-
plored as beneficial to COVID-19 patients with pulmonary
complication, as it increases pulmonary blood flow and
oxygenation in a pig model of lipopolysaccharide-induced
ARDS. Supplementation with ACE2 or inhibition of Ang-II
improves outcomes in acute lung injury. A pilot trial
demonstrated that rhACE2 is well-tolerated in ARDS
patients and showed the anticipated changes in RAS
peptides. Taken together, evidence unequivocally supports
the concept that ACE2 is critical in pulmonary function
and its imbalance in COVID-19 infection contributes to the
devastating lung consequences.
An ACE2 activator, diminazene aceturate (DIZE) is
a known antiprotozoal drug used in humans, but it has
additional benefits including potent anti-inflammatory
Figure 5—Atomic structure of human B0AT1/ACE2 ternary complex bound to spike protein region of SARS-CoV-2. A: The complex
comprises a dimer of heterodimers formed by two B0AT1 subunits (red) contacting with two ACE2 subunits (green), with each ACE2
interfacing with a single SARS-CoV-2 spike (brown). The complex was stabilized using Na1 cotransporter B0AT1 transport substrate leucine
within the center membrane-spanning domain, known to serve tryptophan, glutamine, and other neutral amino acids in addition to leucine.
Intestinal apical membranes express the B0AT1:ACE2 complex, which does not occur in lung pneumocytes (40). B: Side view showing
charged moiety interactions in the extracellular region of the gut lumen (top inset) and also hydrophobic interactions of B0AT1 TM3 and TM4
interacting with the single long transmembrane domain of ACE2 within the apical membrane (bottom inset). Data coordinates were obtained
from pdb ID: 6M17 (18).
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Figure 6—Intestinal epithelial cell RAS and B0AT1 govern glucose, sodium, and inflammation. All RAS components are recapitulated locally
in the gut (41). Luminal agonist and antagonist bioactive peptides are derived from interactions of gut digestive enzymes intertwined with
microbiome metabolism. Oral ARBs and ACEi drugs impact gut RAS. Gut RAS governs sodium and glucose uptake via NHE3, SGLT1, and
GLUT2. The ACE2:B0AT1 complex dimer of heterodimers (18) serves theNa1-coupled transport of neutral amino acids, including tryptophan.
In enteroendocrine L cells, basolateral tryptophan stimulates GLP-1 and GIP secretion. These incretins maintain gut tight junctions,
preventing dysbiosis, stimulate pancreatic b-cells, and blunt a-cells, thereby modulating plasma glucose levels. SARS-CoV-2 binding to
ACE2 disrupts this homeostasis.
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and antifibrotic activity. DIZE has been used in type 1 di-
abetes to prevent nephropathy and gastric inflammation.
DIZE modulated the RAS by reducing serum Ang-II and the
expression of AT1R, but it increased Ang-1-7 (7). DIZE not
only increases ACE2 activity but also increased the expres-
sion of ACE2 in select cell types where DIZE inhibited the
expression of IL-6, IL-8, and MCP-1 at both mRNA and
protein levels following stimulation with lipopolysaccharide.
Collectively, these results show that DIZE downregulates
proinflammatory cytokine production by many distinct cell
types and suggest that this drug may provide benefit to
COVID-19 patients by reducing pulmonary inflammation
and fibrosis, gut inflammation, and cytokine storm.
Conclusion
As the global pandemic unfolds and rapidly spreads, there
is an urgent need for basic and clinical studies to address
the many unanswered questions posed by COVID-19. This
Perspective has directed attention to the disruption of RAS
in the lung, gastrointestinal tract, and bone marrow as
possible mechanisms of SARS-CoV-2 disease pathogenesis.
The dysregulated RAS can potentially impact clinical out-
comes in individuals with diabetes resulting in increased
morbidity and mortality. ACE2 has emerged as the pleio-
tropic regulator of the RAS, by metabolizing Ang-II into
the beneficial peptide Ang-1-7, while being harmful as the
SARS-CoV-2 receptor. Loss of ACE2 indirectly via pro-
teolytic processing, autophagy, and shedding partly could
not only drive lung pathology but also gut disease in
individuals with diabetes infected with COVID-19. SARS-
CoV-2, by downregulating intestinal ACE2-B0AT1, could
promote leaky gut syndrome with elevated plasma bacterial
lipopolysaccharides and/or peptidoglycans enhancing sys-
temic inflammation. Careful targeting of the RAS axis may
represent a strategy for improving clinical outcomes in
subjects with diabetes infected with COVID-19.
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